Treatment of Advanced Hodgkin Lymphoma / 대한내과학회지
Korean Journal of Medicine
;
: 562-568, 2011.
Article
in Korean
| WPRIM
| ID: wpr-162476
ABSTRACT
The major portion of Hodgkin lymphoma (HL) patients, even at an advanced stage can be cured with optimal initial treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard treatment regimen for the advanced stage HL, while Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) and escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) can be reasonable alternatives for selected patients. Although radiotherapy is the key component in Stanford V regimen, radiotherapy should be applied only at the residual lymphoma in patients who received ABVD and BEACOPP therapy. These three representative treatments for advanced HL have individual advantages and disadvantages, so that the choice of the initial treatment should be dependent on patients' relapse risk, comorbidity, and age.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Procarbazine
/
Recurrence
/
Vinblastine
/
Vincristine
/
Bleomycin
/
Hodgkin Disease
/
Doxorubicin
/
Comorbidity
/
Cyclophosphamide
/
Etoposide
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS